FibroScan & Elastography: Liver Stiffness vs Liver Fat

Section accent: --clay (MASLD pillar, scoped in-family).

The one distinction to hold onto: fat is not fibrosis

Elastography is where the fat-versus-fibrosis distinction becomes concrete, because a single FibroScan report hands you two numbers that mean completely different things:

• Liver stiffness (kPa) — a physical surrogate for fibrosis (scarring). This is the number that speaks to risk.
• CAP (Controlled Attenuation Parameter, dB/m) — an estimate of liver fat (steatosis).

Patients (and occasionally reports) blur these. A high CAP means a fatty liver; it says little about scarring. A high kPa suggests fibrosis; it isn't a measure of fat. Liver fat and liver fibrosis are measured differently because they are different things — the central rule of this whole section. → What Is MASLD?

What VCTE / FibroScan actually does

FibroScan is the common brand name for VCTE — vibration-controlled transient elastography. A probe placed on the skin over the liver sends a gentle mechanical pulse and measures how fast the resulting shear wave travels through liver tissue. Stiffer tissue transmits the wave faster. The device converts that speed into a stiffness value in kPa.

It is quick (minutes), painless, radiation-free, and done at the point of care. It measures a physical property of the liver rather than estimating from bloodwork — which is why it's more informative about fibrosis than FIB-4, and why it sits after FIB-4 in the pathway. → The W8Experts Diagnostic Approach

How liver stiffness (kPa) is interpreted

Higher stiffness means a higher probability of significant fibrosis. Interpretation is probabilistic and context-dependent, not a fixed line, and thresholds vary by cause of liver disease and by lab:

• Lower kPa (roughly <8 kPa in MASLD) — advanced fibrosis is unlikely; strong reassurance, especially with a reliable reading.
• Intermediate kPa (roughly ~8–12 kPa) — a grey zone; may prompt repeat testing, MRE, or specialist input.
• Higher kPa (roughly >12 kPa, and >15 kPa often used to flag compensated advanced chronic liver disease) — raises concern for advanced fibrosis; usually prompts hepatology referral and further evaluation.

Treat those numbers as a rule-of-thumb for MASLD, not fixed lines. Two honest caveats: first, kPa is a surrogate — it correlates with fibrosis but isn't a direct scar measurement. Second, the exact cutoffs differ between guidelines, centres, and cause of liver disease, so a specific number should be read against the reporting lab's ranges and your whole clinical picture, not a generic table. And remember the other number on the report: CAP measures hepatic fat (steatosis, in dB/m), not fibrosis — it says nothing about scarring. Any specific threshold should be checked against current guideline/manufacturer values for the relevant disease.

How CAP (fat) is interpreted

CAP estimates how much the ultrasound signal is attenuated by fat — a proxy for steatosis. A higher CAP means more liver fat. It's useful for confirming and roughly grading fat, and for tracking change, but it is not a fibrosis measurement and shouldn't be read as one. For precise fat quantification, MRI-PDFF is more accurate; CAP is the convenient bedside version. → Diagnostic Approach

MRE — the more accurate cousin

MRE (magnetic resonance elastography) measures liver stiffness using MRI rather than a handheld probe. It maps stiffness across much more of the liver and is more accurate than VCTE and less affected by body habitus — but it's costlier, less available, and requires an MRI scanner. Its usual role is for discordant or uncertain cases (for example, an unreliable FibroScan in a person with obesity, or results that don't fit the clinical picture), and in research. Like VCTE, it's a stiffness surrogate, not a biopsy.

The limits — when elastography is unreliable

Elastography is powerful but not infallible. Stiffness can be over- or under-estimated by factors that have nothing to do with permanent scarring:

• Obesity and probe fit. A thick chest wall can make standard-probe readings unreliable or unobtainable; an XL probe helps, and MRE may be needed when FibroScan fails. This matters because the people most likely to have MASLD are also the most likely to challenge the probe.
• Recent food. Eating increases liver blood flow and can transiently raise stiffness, so testing is usually done fasting (commonly ~3 hours).
• Hepatic congestion / heart failure. A congested liver is stiffer independent of fibrosis, inflating kPa.
• Acute hepatitis / marked inflammation, cholestasis, and heavy alcohol use can all raise stiffness.
• Operator technique and an inadequate number of valid readings reduce reliability; reports include quality metrics (e.g., number of valid measurements and variability) that should be checked.

Because of these, a single kPa value is interpreted alongside FIB-4, the metabolic picture, and reliability metrics — not in isolation. → FIB-4 Explained

Where elastography sits: FIB-4 first, then stiffness

Elastography is second-line, deployed when the cheaper first-line filter (FIB-4) is indeterminate or high:

FIB-4  (first-line, from routine bloodwork; age-adjusted ≥65)
   ↓  indeterminate or high
ELASTOGRAPHY  (VCTE/FibroScan kPa — or MRE if FibroScan unreliable/discordant)
   ↓
LOWER  ·  INTERMEDIATE  ·  HIGHER  fibrosis risk
   ↓
MONITOR  ·  INTERVENE  ·  REFER / FURTHER EVALUATE (± biopsy, selectively)

This sequence means most people never need elastography, and even fewer need biopsy — the tests escalate only as risk rises. → The W8Experts Diagnostic Approach · Liver Biopsy: When It's Needed

SIGNATURE — "What the evidence says: Elastography"

• What we know: VCTE/FibroScan liver stiffness is a validated fibrosis surrogate that meaningfully improves risk stratification after FIB-4; CAP estimates fat separately; MRE is the most accurate noninvasive stiffness measure.
• What we think: Used as a second-line test with attention to reliability, elastography safely reduces the need for biopsy.
• What we don't know: The single best universal cutoffs, and how reliably repeated stiffness tracks true fibrosis change over time — especially in obesity.
• What patients should do: Read the two numbers separately (kPa = scarring surrogate, CAP = fat), fast beforehand, and interpret any result with a clinician and its reliability metrics — not as a standalone verdict. → FIB-4 Explained

Questions patients ask

KEEP READING

• FIB-4 Explained — the first-line score that decides whether you need elastography.
• The W8Experts Diagnostic Approach — where stiffness testing fits in the full pathway.
• What Is MASLD? — the fat-versus-fibrosis distinction, from the start.
• Liver Biopsy: When It's Needed — the reference standard, used selectively.
• "My Liver Tests Are Normal…" — why enzymes don't answer the fibrosis question.

Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: AASLD Practice Guidance on MASLD (2023); EASL–EASD–EASO clinical practice guidance; manufacturer and guideline documentation for VCTE/CAP and MRE. Specific kPa/CAP thresholds should be verified against current guideline and device references. Educational; not a diagnosis.